Figure 6. In vivo efficacy of BocNHO in an orthotopic lung tumor model. Bioluminescence imaging, as measured in total flux (photons/second, p/s), was performed on Day 3 to establish the baseline tumor burden for each mouse. Subsequent bioluminescence imaging of mice treated with 60 µg/kg BocNHO (●) or vehicle (■) on Days 11, 20 and 32 was used to quantify percent change in tumor burden relative to the baseline tumor burden over time (B). A statistically significant decrease in percent tumor burden was observed at Days 20 and 32 following treatment with BocNHO compared with vehicle-treated animals. Bioluminescence images revealing decreased tumor burden of mice treated with the BocNHO prodrug [(A), top] compared with vehicle-treated mice [(A), bottom] are shown from Day 32. As a measure of gross toxicity, body weights of mice treated with BocNHO (●) or vehicle (■) were compared (C). As early as day 5, a significant decrease in body weight is observed in mice treated with the BocNHO prodrug compared with vehicle-treated mice. Single (*) asterisks represent significant unpaired t-test p values of < 0.05.